Oncology

Prevalence of Germline Mutations in Consecutive, Unselected Patients with Newly Diagnosed Adenocarcinoma of the Pancreas.

  • Identifying mutation carriers may provide potential targets for personalized treatment with agents such as PARP and immune checkpoint inhibitors and allows for recognition of family members who may benefit from pancreatic and other cancer screening and prevention strategies.
  • 5.5% of newly diagnosed unselected patients carry pathogenic mutation in genes known to contribute to pancreatic cancer risk (APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53). This information will be updated in the poster presentation at DDW.

  • Authors: Randall Brand; Nadine Tung; Beth Dudley; Eve Karloski; Mary Linton Peters; Lindsey Stobie; Erkut Borazanci; A.J. Moser; Arlene Colvin; Cynthia Lim; Melissa E. Hogg; Kenneth Lee; J. Wallis Marsh; Allan Tsung; Herbert J. Zeh; Amer H. Zureikat; Courtney Grosvenor; Brigette Tippin Davis; Holly LaDuca; Jill Dolinsky; Emily Dalton; Mary Helen Black; Virginia Speare
  • Conference: Digestive Disease Week (DDW)
  • Date: Saturday, May 06, 2017 12:00pm - 2:00pm

Search Results

Start your search...